113 related articles for article (PubMed ID: 17972171)
21. BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer.
Sabatier R; Adélaïde J; Finetti P; Ferrari A; Huiart L; Sobol H; Chaffanet M; Birnbaum D; Bertucci F
Genes Chromosomes Cancer; 2010 Dec; 49(12):1143-51. PubMed ID: 20842729
[TBL] [Abstract][Full Text] [Related]
22. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of PALB2 mutations in Australian familial breast cancer cases and controls.
Thompson ER; Gorringe KL; Rowley SM; Wong-Brown MW; McInerny S; Li N; Trainer AH; Devereux L; Doyle MA; Li J; Lupat R; Delatycki MB; ; Mitchell G; James PA; Scott RJ; Campbell IG
Breast Cancer Res; 2015 Aug; 17(1):111. PubMed ID: 26283626
[TBL] [Abstract][Full Text] [Related]
24. Mutation analysis of PALB2 gene in French breast cancer families.
Damiola F; Schultz I; Barjhoux L; Sornin V; Dondon MG; Eon-Marchais S; Marcou M; ; Caron O; Gauthier-Villars M; de Pauw A; Luporsi E; Berthet P; Delnatte C; Bonadona V; Maugard C; Pujol P; Lasset C; Longy M; Bignon YJ; Fricker JP; Andrieu N; Sinilnikova OM; Stoppa-Lyonnet D; Mazoyer S; Muller D
Breast Cancer Res Treat; 2015 Dec; 154(3):463-71. PubMed ID: 26564480
[TBL] [Abstract][Full Text] [Related]
25. Functional analysis of clinical
Toh MR; Chong ST; Chan SH; Low CE; Ishak NDB; Lim JQ; Courtney E; Ngeow J
Cold Spring Harb Mol Case Stud; 2019 Aug; 5(4):. PubMed ID: 31371347
[TBL] [Abstract][Full Text] [Related]
26. Summary of
Suszynska M; Kozlowski P
Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32679805
[TBL] [Abstract][Full Text] [Related]
27. Analysis of large mutations in BARD1 in patients with breast and/or ovarian cancer: the Polish population as an example.
Klonowska K; Ratajska M; Czubak K; Kuzniacka A; Brozek I; Koczkowska M; Sniadecki M; Debniak J; Wydra D; Balut M; Stukan M; Zmienko A; Nowakowska B; Irminger-Finger I; Limon J; Kozlowski P
Sci Rep; 2015 May; 5():10424. PubMed ID: 25994375
[TBL] [Abstract][Full Text] [Related]
28. ATM variants and cancer risk in breast cancer patients from Southern Finland.
Tommiska J; Jansen L; Kilpivaara O; Edvardsen H; Kristensen V; Tamminen A; Aittomäki K; Blomqvist C; Børresen-Dale AL; Nevanlinna H
BMC Cancer; 2006 Aug; 6():209. PubMed ID: 16914028
[TBL] [Abstract][Full Text] [Related]
29. Cancer predisposing BARD1 mutations affect exon skipping and are associated with overexpression of specific BARD1 isoforms.
Ratajska M; Matusiak M; Kuzniacka A; Wasag B; Brozek I; Biernat W; Koczkowska M; Debniak J; Sniadecki M; Kozlowski P; Klonowska K; Pilyugin M; Wydra D; Laurent G; Limon J; Irminger-Finger I
Oncol Rep; 2015 Nov; 34(5):2609-17. PubMed ID: 26329992
[TBL] [Abstract][Full Text] [Related]
30. A cross-sectional study of associations between nonsynonymous mutations of the BARD1 gene and breast cancer in Han Chinese women.
Liu H; Zhang H; Sun X; He Y; Li J; Guo X
Asia Pac J Public Health; 2013 Jul; 25(4 Suppl):8S-14S. PubMed ID: 23966609
[TBL] [Abstract][Full Text] [Related]
31. RNA assay identifies a previous misclassification of BARD1 c.1977A>G variant.
Rofes P; Pineda M; Feliubadaló L; Menéndez M; de Cid R; Gómez C; Montes E; Capellá G; Brunet J; Del Valle J; Lázaro C
Sci Rep; 2021 Nov; 11(1):22948. PubMed ID: 34824355
[TBL] [Abstract][Full Text] [Related]
32. Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance.
Surowy HM; Sutter C; Mittnacht M; Klaes R; Schaefer D; Evers C; Burgemeister AL; Goehringer C; Dikow N; Heil J; Golatta M; Schott S; Schneeweiss A; Bugert P; Sohn C; Bartram CR; Burwinkel B
Breast Cancer Res Treat; 2014 Jun; 145(2):451-60. PubMed ID: 24728577
[TBL] [Abstract][Full Text] [Related]
33. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
34. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
[TBL] [Abstract][Full Text] [Related]
35. Association of rare MSH6 variants with familial breast cancer.
Wasielewski M; Riaz M; Vermeulen J; van den Ouweland A; Labrijn-Marks I; Olmer R; van der Spaa L; Klijn JG; Meijers-Heijboer H; Dooijes D; Schutte M
Breast Cancer Res Treat; 2010 Sep; 123(2):315-20. PubMed ID: 19924528
[TBL] [Abstract][Full Text] [Related]
36. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
[TBL] [Abstract][Full Text] [Related]
37. Lack of association between BARD1 Cys557Ser variant and breast cancer risk: a meta-analysis of 11,870 cases and 7,687 controls.
Ding DP; Zhang Y; Ma WL; He XF; Wang W; Yu HL; Guo YB; Zheng WL
J Cancer Res Clin Oncol; 2011 Oct; 137(10):1463-8. PubMed ID: 21809034
[TBL] [Abstract][Full Text] [Related]
38. BARD1, a possible biomarker for breast and ovarian cancer.
Irminger-Finger I
Gynecol Oncol; 2010 May; 117(2):211-5. PubMed ID: 19959210
[TBL] [Abstract][Full Text] [Related]
39. Analysis of KLLN as a high-penetrance breast cancer predisposition gene.
Thompson ER; Gorringe KL; Choong DY; Eccles DM; ; Mitchell G; Campbell IG
Breast Cancer Res Treat; 2012 Jul; 134(2):543-7. PubMed ID: 22580995
[TBL] [Abstract][Full Text] [Related]
40. The PALB2 gene is a strong candidate for clinical testing in BRCA1- and BRCA2-negative hereditary breast cancer.
Janatova M; Kleibl Z; Stribrna J; Panczak A; Vesela K; Zimovjanova M; Kleiblova P; Dundr P; Soukupova J; Pohlreich P
Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2323-32. PubMed ID: 24136930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
